Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [11347]

NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody

NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody

University develops novel bone cancer therapy which has 99% success rate

University develops novel bone cancer therapy which has 99% success rate

Can chatbots help with genetic testing for cancer risk?

Can chatbots help with genetic testing for cancer risk?

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS...

MicroDicer and MicroGrater make quick work of tumour dissection

MicroDicer and MicroGrater make quick work of tumour dissection

ESMO 2024: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

ESMO 2024: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone...

Evolving the framework of cancer theory

Evolving the framework of cancer theory

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...

Chemical screen identifies PRMT5 as therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer

Chemical screen identifies PRMT5 as therapeutic vulnerability for paclitaxel-resistant triple-negative breast...

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...

More from ecancer